Blockage of EGFR Pathway for Anticancer Therapy in Squamous Cell Carcinoma of the Head and Neck

Schmitz, Sandra; Machiels, Jean‐Pascal

doi:10.1007/978-94-024-1084-6_6

Cited by 1 publication

(1 citation statement)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…gefitinib, erlotinib), which may be used in combination with other therapies. 51 With biologically guided tumour characterization, personalized treatment protocols can be designed for individual patients…”

Section: Discussionmentioning

confidence: 99%

Expression and clinical significance of the receptors of the EGF family in oral squamous cell carcinomas

Dissanayeke

2019

Translational Research in Oral Oncology

View full text Add to dashboard Cite

Objective: To examine the immunohistochemical expression of four members of the type 1 growth factor receptor family in oral squamous cell carcinomas (OSCCs) and to correlate with clinical outcomes. Materials and methods: Sixty OSCCs from a patient cohort in Sri Lanka were included in the study. Five sections from each carcinoma were immunostained with antibodies to epidermal growth factor receptor (EGFR)/c-erbB-1, c-erbB-2/HER-2/neu, c-erbB-3/HER-3 and c-erbB-4/HER-4. Two clones were used to stain for c-erbB-2/HER-2/neu. Semiquantitative analysis of immunoreactivity was carried out by scoring the intensity of expression and proportions of positively stained cells. A logistic regression analysis was performed to examine positive expression against overall survival. Results: There was heterogenous expression of the four receptors, positivity ranging from 26% to 60%. Co-expression of all four markers was observed only in 1-3% of the tumours. Both membranous and cytoplasmic expressions were observed, EGFR showing predominantly membranous expression and c-erbB-2 showing only cytoplasmic staining. In logistic regression analysis, none of the growth factor receptors were significantly predictive of overall survival. Conclusion: Type 1 growth factor receptors are highly expressed in oral carcinomas, EGFR being the predominant marker.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression and clinical significance of the receptors of the EGF family in oral squamous cell carcinomas

Dissanayeke

2019

Translational Research in Oral Oncology

View full text Add to dashboard Cite

show abstract

Blockage of EGFR Pathway for Anticancer Therapy in Squamous Cell Carcinoma of the Head and Neck

Cited by 1 publication

References 122 publications

Expression and clinical significance of the receptors of the EGF family in oral squamous cell carcinomas

Expression and clinical significance of the receptors of the EGF family in oral squamous cell carcinomas

Contact Info

Product

Resources

About